Vera Therapeutics’ Trutakna Poised for Full FDA Approval in IgAN Following Robust Confirmatory Data

Vera Therapeutics’ Trutakna (atacicept-vymj) is on a strong trajectory towards full United States Food and Drug Administration (FDA) approval for the treatment of primary IgA nephropathy (IgAN), also known as Berger’s disease. The company announced compelling data from its pivotal Phase III ORIGIN 3 trial, which not only reinforces the accelerated approval granted in July 2026 but also signals a significant advancement in the management of this chronic kidney disease.

n

Main Facts:

n

Vera Therapeutics has presented robust confirmatory data from its Phase III ORIGIN 3 trial, demonstrating Trutakna’s sustained efficacy in patients with primary IgA nephropathy (IgAN). The trial’s results at 52 and 104 weeks show a significant slowing of kidney function decline and a reduction in disease progression compared to placebo. This data is expected to support Vera Therapeutics’ supplemental Biologics License Application (sBLA) for full FDA approval, which the company plans to submit in the fourth quarter of 2026, with potential full approval anticipated in 2027. The drug, an inhibitor of B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), has already garnered substantial interest from physicians and patients since its accelerated approval for proteinuria reduction.

n

Chronology of Approval and Data Milestones:

n

The journey of Trutakna towards full FDA approval has been marked by key milestones, beginning with its initial accelerated approval and culminating in the release of comprehensive confirmatory data.

n

n
• n

  July 2026: The U.S. Food and Drug Administration (FDA) grants Trutakna (atacicept-vymj) accelerated approval. This decision was based on an interim analysis of the Phase III ORIGIN 3 trial, specifically demonstrating Trutakna’s ability to reduce proteinuria in adults with primary IgAN who are at risk for disease progression. The interim data at 36 weeks showed a statistically significant and clinically meaningful 42% reduction in proteinuria compared to placebo, representing a 46% reduction from baseline in the treatment arm. This accelerated approval allowed for earlier patient access to a potentially life-altering therapy.

  n

n

• n

  Ongoing Development and Confirmatory Data: Following the accelerated approval, Vera Therapeutics continued to gather data from the ORIGIN 3 trial to support full approval. The trial’s design included long-term follow-up to assess sustained efficacy and safety.

  n

n

• n

  Recent Data Presentation (52-week and 104-week endpoints): The latest data presented from the ORIGIN 3 trial provides a comprehensive view of Trutakna’s long-term impact.

  n

  n
  • At 52 weeks, patients treated with Trutakna experienced a significantly smaller decline in mean estimated glomerular filtration rate (eGFR) change from baseline. The reduction was a mere 0.1 mL/min/1.73m², starkly contrasting with the 5.7 mL/min/1.73m² reduction observed in the placebo group. This substantial difference highlights Trutakna’s potential to preserve kidney function over time.

  n

  • Looking at the longer term, the annualised eGFR slope through 104 weeks further solidified Trutakna’s benefit. In the treatment arm, the annualised decline was only 0.6 mL/min/1.73m², while the placebo cohort experienced a more pronounced drop of 5.6 mL/min/1.73m². This sustained slowing of eGFR decline is a critical indicator of disease modification.

  n

  n

n

• n

  Reduction in Kidney Disease Progression: Beyond eGFR, the confirmatory data also demonstrated Trutakna’s positive impact on preventing severe kidney disease progression.

  n

  n
  • Crucially, no patients in the Trutakna treatment group required dialysis for more than 30 days or a kidney transplant during the study period. In contrast, eight patients in the placebo cohort experienced these severe outcomes.

  n

  • The composite endpoint for kidney disease progression also showed a significant reduction, with 11 events reported in the Trutakna group compared to 38 events in the placebo group. This suggests a broad protective effect of Trutakna against various markers of advanced kidney disease.

  n

  n

n

• n

  Proteinuria, Gd-IgA1, and Haematuria: Trutakna also achieved statistically significant reductions in other key markers of IgAN activity. The drug demonstrated success in hierarchically tested endpoints, including:

  n

  n
  • Proteinuria: This was the basis for the initial accelerated approval and the confirmatory data continues to show significant reductions.
  • Galactose-deficient IgA1 (Gd-IgA1): Gd-IgA1 is a hallmark biomarker in IgAN pathogenesis. Reductions in this marker suggest Trutakna is addressing the underlying immune dysregulation.
  • Haematuria: The presence of blood in the urine is another indicator of kidney inflammation and damage. Trutakna’s ability to reduce haematuria further underscores its therapeutic impact.

• Fourth Quarter 2026: Vera Therapeutics plans to submit its supplemental Biologics License Application (sBLA) to the FDA, seeking full approval for Trutakna.

• Anticipated 2027: Based on the strength of the confirmatory data and the regulatory pathway, Vera Therapeutics anticipates potential full FDA approval for Trutakna in 2027.

Supporting Data: A Deep Dive into Trutakna’s Efficacy

The efficacy of Trutakna in IgAN is underpinned by a wealth of data emerging from the Phase III ORIGIN 3 trial. The trial’s robust design and the consistent positive outcomes across multiple endpoints paint a clear picture of the drug’s therapeutic potential.

Preserving Kidney Function: The eGFR Advantage

The estimated glomerular filtration rate (eGFR) is a critical measure of kidney function. A declining eGFR indicates progressive kidney damage. Trutakna has demonstrated a remarkable ability to significantly slow this decline, thereby preserving precious kidney function for patients.

• At 52 Weeks: The difference in eGFR change between Trutakna and placebo at the 52-week mark is particularly striking. A reduction of only 0.1 mL/min/1.73m² in the Trutakna arm, compared to a substantial 5.7 mL/min/1.73m² in the placebo arm, translates to a substantial preservation of kidney function. This difference suggests that early intervention with Trutakna can meaningfully alter the disease’s trajectory.

• Long-Term Impact at 104 Weeks: The annualised eGFR slope through 104 weeks further solidifies Trutakna’s long-term benefit. The minimal drop of 0.6 mL/min/1.73m² in the treatment group, versus a 5.6 mL/min/1.73m² drop in the placebo group, highlights the sustained protective effect of Trutakna. This long-term data is crucial for patients and clinicians making treatment decisions for a chronic condition like IgAN.

Halting Disease Progression: Beyond eGFR

Trutakna’s impact extends beyond simply slowing eGFR decline; it demonstrably reduces the risk of severe kidney disease progression.

• Avoiding Dialysis and Transplant: The most compelling evidence of Trutakna’s disease-modifying potential lies in its ability to prevent the need for renal replacement therapy. The absence of patients requiring dialysis for more than 30 days or kidney transplant in the Trutakna group, contrasted with eight such events in the placebo group, is a profound testament to the drug’s efficacy in averting end-stage renal disease.

• Reduced Composite Kidney Disease Progression: The composite endpoint, which aggregates various measures of disease worsening, also showed a significant benefit. With 11 events in the treatment group versus 38 in the placebo cohort, Trutakna clearly demonstrates a comprehensive reduction in the likelihood of experiencing significant kidney damage.

Targeting Pathophysiology: Biomarker Reductions

Trutakna’s mechanism of action, targeting the key cytokines BAFF and APRIL, is directly reflected in its ability to reduce specific biomarkers associated with IgAN pathogenesis.

• Proteinuria: As the primary endpoint for the accelerated approval, Trutakna’s significant reduction in proteinuria is a well-established benefit. This reduction signifies a decrease in the leakage of protein from the kidneys, a hallmark of glomerular damage.

• Galactose-deficient IgA1 (Gd-IgA1): The reduction in Gd-IgA1 levels is particularly significant. This glycoform of IgA1 is thought to play a central role in IgAN pathogenesis by forming immune complexes that deposit in the kidneys. Inhibiting the production or activity of BAFF and APRIL, which are involved in B-cell function and antibody production, can lead to a decrease in these pathogenic immune complexes.

• Haematuria: The reduction in haematuria further supports Trutakna’s anti-inflammatory and protective effects on the kidney glomeruli.

Official Responses and Clinical Significance

The release of this robust confirmatory data has elicited strong positive responses from both Vera Therapeutics and the broader medical community.

Dr. Marshall Fordyce, founder and CEO of Vera Therapeutics, expressed immense satisfaction with the trial results: “We believe that upstream inhibition of BAFF and APRIL with Trutakna achieves results that reflect the potential for comprehensive disease modification in IgAN. The final results support this alignment, and we plan to submit the supplemental BLA in the fourth quarter of this year. We look forward to the potential full approval of Trutakna in 2027.”

This statement underscores the company’s confidence in Trutakna’s ability to offer a disease-modifying therapy rather than just symptom management. The drug’s mechanism of action, targeting the upstream drivers of IgAN, appears to be translating into meaningful clinical outcomes.

The strong patient and physician interest since Trutakna’s accelerated approval is also a significant indicator. In the mere 10 weeks following its initial clearance, Vera Therapeutics received over 350 patient start forms, suggesting a high unmet need and a positive reception to the new therapeutic option. This early uptake reflects the enthusiasm for a treatment that addresses the underlying disease processes in IgAN.

Implications for the IgAN Market and Patient Care

The success of Trutakna has significant implications for the rapidly evolving IgA nephropathy market and, more importantly, for the patients living with this debilitating condition.

A Crowded but Growing Field:

The IgAN therapeutic landscape is becoming increasingly competitive, with several promising agents advancing through clinical development and gaining regulatory approval. This growing interest from pharmaceutical companies highlights the significant unmet need and the potential for substantial commercial success in this area.

• Otsuka’s Voyxact (sibeprenlimab-szsi): In August 2026, Otsuka Pharmaceuticals presented positive two-year data for Voyxact, another IgAN therapeutic. The Phase III VISIONARY trial showed that Voyxact stabilized kidney function in IgAN patients, with an annualised estimated eGFR slope of 0.3 mL/min/1.73m²/year compared to a 4.2 mL/min/1.73m²/year reduction with placebo. This further validates the strategy of targeting specific pathways involved in IgAN.

• Novartis’ Vanrafia (atrasentan): In February 2026, Novartis shared final data from its Phase III ALIGN trial of Vanrafia. This trial demonstrated a 2.39 mL/min/1.73m² difference in eGFR change from baseline compared to placebo at week 136, even after treatment cessation. Novartis indicated its intention to seek full FDA approval based on these findings.

• Vertex’s Povetacicept: In March 2026, Vertex Pharmaceuticals announced its intention to seek approval for povetacicept, a dual inhibitor of BAFF and APRIL, following success in its Phase III RAINER trial. This further emphasizes the therapeutic potential of targeting these key cytokines in IgAN.

• Established Therapies: More established therapies, such as Calliditas Therapeutics’ Tarpeyo (budesonide) and Travere Therapeutics’ Filspari (sparsentan), have already navigated the regulatory pathway to full FDA approval, demonstrating that effective treatments are becoming available. Tarpeyo received accelerated approval in 2021 and full approval in December 2023, while Filspari gained accelerated approval in 2023 and full approval in September 2024.

The Role of Trutakna:

Trutakna’s unique mechanism of action as a TACI receptor inhibitor, directly binding to BAFF and APRIL, offers a distinct approach to IgAN management. The comprehensive data from the ORIGIN 3 trial, demonstrating not only proteinuria reduction but also significant slowing of eGFR decline and prevention of severe disease progression, positions Trutakna as a potentially cornerstone therapy.

Impact on Patient Care:

For patients with IgAN, the increasing availability of effective treatments like Trutakna represents a paradigm shift. Previously, management primarily focused on supportive care, including blood pressure control and immunosuppression, with limited options to halt or reverse disease progression.

The availability of Trutakna, with its demonstrated ability to:

• Preserve kidney function: Extending the time before patients require dialysis or transplantation.
• Reduce the risk of severe complications: Minimizing the burden of end-stage renal disease.
• Address the underlying disease mechanisms: Offering a more targeted and potentially disease-modifying approach.

The strong physician and patient interest suggests a significant unmet need is being met. As Trutakna moves towards full FDA approval, it is poised to become a vital tool in the armamentarium against IgA nephropathy, offering renewed hope for improved long-term outcomes and enhanced quality of life for individuals affected by this chronic and progressive kidney disease. The continued research and development in this area promise a brighter future for IgAN patients worldwide.